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Pro-invasive stimuli and the 
interacting protein Hsp70 favour 
the route of alpha-enolase to the 
cell surface
Giovanni Perconti1, Cristina Maranto1, Daniele P. Romancino1, Patrizia Rubino1, Salvatore 
Feo1,2, Antonella Bongiovanni1 & Agata Giallongo1
Cell surface expression of alpha-enolase, a glycolytic enzyme displaying moonlighting activities, has 
been shown to contribute to the motility and invasiveness of cancer cells through the protein non-
enzymatic function of binding plasminogen and enhancing plasmin formation. Although a few recent 
records indicate the involvement of protein partners in the localization of alpha-enolase to the plasma 
membrane, the cellular mechanisms underlying surface exposure remain largely elusive. Searching for 
novel interactors and signalling pathways, we used low-metastatic breast cancer cells, a doxorubicin-
resistant counterpart and a non-tumourigenic mammary epithelial cell line. Here, we demonstrate 
by a combination of experimental approaches that epidermal growth factor (EGF) exposure, like 
lipopolysaccharide (LPS) exposure, promotes the surface expression of alpha-enolase. We also establish 
Heat shock protein 70 (Hsp70), a multifunctional chaperone distributed in intracellular, plasma 
membrane and extracellular compartments, as a novel alpha-enolase interactor and demonstrate a 
functional involvement of Hsp70 in the surface localization of alpha-enolase. Our results contribute to 
shedding light on the control of surface expression of alpha-enolase in non-tumourigenic and cancer 
cells and suggest novel targets to counteract the metastatic potential of tumours.
An increasing number of proteins are being identified as multifunctional1. Most of these are enzymes, which 
in addition to their catalytic function are involved in fully unrelated processes, such as the glycolytic enzyme 
alpha-enolase, which was one of the first moonlighting proteins to be identified2. Multiple subcellular locali-
zations characterize alpha-enolase, which functions as a plasminogen receptor when localized on the cell sur-
face, and available data have demonstrated its interaction with plasminogen in prokaryotic and eukaryotic cells3. 
Mammalian tumour cells use the activation of plasminogen in plasmin to invade tissue and form metastases4. 
Recently, researchers have linked both pericellular plasminogen activation and cell surface alpha-enolase to 
migration and invasion in lung and pancreatic cancer, and these studies have proposed targeting cancer cells with 
specific anti-alpha-enolase antibodies as a promising approach to suppress tumour metastasis5, 6. Due to the large 
interest in novel therapeutic strategies to counteract cancer spreading, stimuli and signalling pathways that can 
cooperate to induce the surface localization of alpha-enolase are attractive objects of study.
Increased expression of surface alpha-enolase following LPS exposure was originally reported for the U937 
macrophage cell line and human blood monocytes7. LPS, a component of the outer membrane of Gram-negative 
bacteria, exerts its biological effects by binding to Toll-like receptor 4 (TLR4), a recognition receptor of the innate 
immune system. Some evidence shows that functional TLR4 receptors are expressed on a variety of tumours, 
including breast cancer, where the silencing of TLR4 results in decreased cellular growth and proliferation, 
whereas its stimulation promotes tumourigenesis and metastatic lesions8, 9. So far, one single report has shown 
that the LPS triggers the translocation of alpha-enolase to cell surface in breast cancer cell lines and, in addition to 
LPS, positively correlated this upregulation to other stimuli promoting tumour progression, such as Transforming 
growth factor (TGF)-β, Tumor necrosis factor (TNF)-α and chemokine ligand 2 (CCL2)10.
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EGF-induced signalling is also commonly associated with tumour growth, and the overexpression of EGF 
receptor (EGFR) family members is reported in many human tumours, including lung, colon and breast car-
cinoma11. It is well documented that EGFR activation induces cancer cell migration and invasion, promot-
ing epithelial-mesenchymal transition (EMT) and metastasis12; however, to date, no association between the 
pro-invasive function of EGF and the increased surface expression of alpha-enolase has been reported.
Despite the existence of several reports indicating the active role of surface alpha-enolase in driving cancer cell 
invasion and metastasis formation, the molecular mechanisms underlying its transport from cytoplasm to cell 
membrane are still the object of hypotheses and speculative models. The lack of canonical membrane localization 
signals in the alpha-enolase sequence has suggested the involvement of export routes of non-classically secreted 
proteins, such as membrane blebbing, membrane flip-flop, endosomal recycling and/or physical association with 
other proteins that mediate transport to the cell surface13. Recently, Zakrzewic and colleagues demonstrated the 
interaction with caveolae-associated proteins, namely caveolin 1 (Cav-1) and Annexin 2 (Annx2), as well as the 
functional role of both proteins in the subcellular localization of alpha-enolase and, consequently, in the regula-
tion of cell migration and invasion mediated by surface alpha-enolase14.
With the aim of identifying additional signalling pathways and protein partner interactions underlying cell 
surface localization of alpha-enolase, we applied biochemical and cell biology approaches to three cell lines 
resembling non-tumourigenic mammary epithelial cells, and low- and high-invasive breast cancer cytotypes. 
We provide evidence that EGF-signalling upregulates cell surface alpha-enolase, independently of metastatic 
potential, and identify Hsp70 as a novel interacting partner that favours alpha-enolase localization to the plasma 
membrane.
Results
EGF increases cell migration and up-regulates the expression of alpha-enolase in the cell mem-
brane fraction. The expression of alpha-enolase is elevated on the cell surface of cancer cells, and it has been 
reported that LPS treatment contributes to protein translocation from the cytoplasm to the plasma membrane 
and extracellular space10. To investigate a possible association between EGF-mediated invasion and the upreg-
ulation of alpha-enolase in the membrane compartment, we chose the HB2 mammary epithelial cell line15 and 
the MCF-7 low metastatic breast cancer cell line. Preliminary western blot analyses confirmed the molecular 
characteristics of the two cell lines, such as different levels of EGF and TLR4 receptors, low/absent expression of 
vimentin, and a discrete level of alpha-enolase (as shown later in this report), features that made them particularly 
suitable for a comparative study of effects due to EGF and LPS exposure.
We firstly analysed the effects of EGF or LPS on cell motility by in vitro wound healing assay. As shown in 
Fig. 1a, the migratory capacity of EGF- or LPS-treated HB2 and MCF-7 cells considerably increased compared to 
the untreated control cells after 6 h of exposure, and a complete closure was observed in both cases after 24 hours 
(Fig. 1a). No significant difference in the response of the two cell lines to either EGF or LPS was observed. To 
investigate a putative correlation between EGFR signalling activation and the expression of alpha-enolase on the 
cell membrane, we performed a cell fractionation that separated the cytoplasmic fraction and the total membrane 
fraction. HB2 and MCF-7 cells were treated with EGF or, as a control, with increasing doses of LPS, and then 
the subcellular fractions were isolated as described in the methods section. Western blot analyses of cytoplasmic 
Heat shock protein 90 (Hsp90) and plasma membrane E-cadherin were used to estimate proper fractionation, 
while the expression level of active pAKT and pERK1/2 kinases confirmed the effectiveness of the treatments 
(Fig. 1b) and filter staining allowed normalization for equal protein loading (supplementary Fig. 1). Following 
both treatments, the expression of alpha-enolase protein in the membrane subcellular fraction increased com-
pared to the untreated controls, whereas no detectable increase of GAPDH was observed in response to EGF or 
LPS. Furthermore, we detected a concentration-dependent response to LPS exposure in both cell lines (Fig. 1b,c). 
The cytoplasmic alpha-enolase levels were unaltered in all conditions (Fig. 1b,c), confirming that the increased 
expression is not due to an overall rise of alpha-enolase protein in the cell and supporting the finding that EGF, 
like LPS treatment, selectively modulates alpha-enolase membrane localization.
EGF increases the localization of alpha-enolase on the plasma membrane, functional conse-
quences on cell invasion. As previously mentioned, the presence of alpha-enolase on the plasma mem-
brane of monocytes has been well-documented in vitro and in vivo following inflammatory stimuli7; moreover, 
the association of enolase with the mitochondrial membrane has been reported in yeast and mammalian cardio-
myocytes16–18. The experimental approach we preliminarily used to evaluate the EGF- or LPS-mediated increase 
of alpha-enolase in the membrane subcellular fraction did not allow discrimination between the plasma mem-
brane and internal membranes. Thus, we decided to use a live immunostaining approach to monitor cell surface 
alpha-enolase. Firstly, we identified an antibody, among several commercially available antibodies, that recog-
nizes an epitope of alpha-enolase exposed on the cell surface, and then we developed a protocol for the staining 
of live cells that allowed the detection of alpha-enolase expression on the cell surface without interference from 
the highly abundant cytoplasmic counterpart. Immunofluorescence analysis indicated that EGF or LPS treatment 
increases the amount of alpha-enolase localized in the plasma membrane of both HB2 and MCF-7 cells. The 
co-localization of alpha-enolase with E-cadherin, a widely used marker of epithelial cells in the plasma mem-
brane, supported the result (Fig. 2a). A computer-assisted image analysis of the immunostained cells indicated 
that, following EGF or LPS exposure, alpha-enolase levels on the cell membrane were approximately three-times 
higher when compared to untreated controls (Fig. 2b). To evaluate the impact of enhanced surface alpha-enolase 
on the invasion capacity of HB2 and MCF-7 cells, a matrigel invasion assay was performed. For both cell lines, 
the number of cells that migrated in response to EGF or LPS was significantly higher than that for unexposed 
cells (Fig. 2c,d). In the presence of monoclonal6, 19 or polyclonal antibodies against alpha-enolase, the EGF- and 
LPS-dependent invasiveness of MCF-7 cell was considerably reduced (Fig. 2e). Specific-antibodies addition 
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Figure 1. EGF and LPS promote cell migration and the up-regulation of alpha-enolase in the membrane 
fraction of non-tumourigenic and cancer cells. (a) A wound-healing assay was performed to observe changes 
in the migratory ability of non-tumourigenic HB2 and low metastatic MCF-7 cells after stimulation with 0.1 µg/
ml of either EGF or LPS for the indicated length of time. Migration at the edge of the scratch was analysed at 
0, 6 and 24 hours, when microscopy images were captured (magnification, 100x, top panel). Cell motility was 
quantified by measuring the scratch wound, and results are expressed relative to total closure (100%). Each 
bar represents the mean ± standard deviation of three independent experiments (lower panel). (b) HB2 and 
MCF-7 cells were treated with the indicated EGF or LPS concentrations for 24 hours, after fractionation cell 
equivalents of cytoplasmic (C) and total membrane (M) fractions were separated by SDS-PAGE and analysed by 
immunoblotting. E-cadherin (E-cad) and Hsp90 were used to estimate proper fractionation, pAKT and pERK 
to confirm the effectiveness of treatments. Changes in alpha-enolase (α-Eno) expression levels were analysed 
in treated versus untreated (−) cells, and GAPDH was used as a further control. (c) Quantification of alpha-
enolase in cytoplasmic and total membrane fractions. Data were normalised to the densitometric signals of 
Ponceau staining (see Supplementary Fig. 1) and expressed relative to the untreated control, set at 1. Each data 
point is the average of three independent experiments, error bars represent standard deviation and p values 
(*P < 0.05, **P < 0.01, ***P < 0.001) indicate statistical significance.
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Figure 2. EGF exposure, like LPS treatment, positively affects the cell surface localization of alpha-enolase 
supporting cell invasion. (a) HB2 and MCF-7 cells were treated with 0.1 µg/ml of EGF or 5 µg/ml of LPS 
for 24 hours, then double-stained with antibodies against alpha-enolase (α-Eno, green, live staining) and 
E-cadherin (red, staining after cell fixation), and visualized by confocal microscopy. The merged images (right 
panels) indicate co-localization of the two proteins. (b) Fluorescence signals were measured in control and 
treated cells using the ImageJ image-processing program. Each bar represents the mean ± standard deviation 
of three independent experiments. (c–f) Matrigel invasion assays. Unstimulated (Control) and EGF- or LPS- 
stimulated cells were allowed to invade for 48 hours, (c) representative images of cells on the underside of the 
transwell membrane and (d) quantification of cells that invaded. (e,f) Effect of anti-alpha-enolase antibodies on 
migration through Matrigel-coated transwell filters. MCF-7 cells were seeded in serum-free medium containing 
isotype-control antibody (isotype Ab) or anti-alpha-enolase monoclonal (α-Eno mAb, 50 µg/ml) and polyclonal 
(α-Eno pAb, 15 µg/ml) antibody and incubated in the absence or presence of EGF (0.1 µg/ml) or LPS (5 µg/
ml) for 24 hours. (f) Quantification of invaded cells is shown relative to the untreated control, set at 1. Results 
are from three independent experiments, error bars represent standard deviation and p values (*P < 0.05, 
**P < 0.01, ***P < 0.001) indicate statistical significance.
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led to a 25% to 40% reduction in the number of MCF-7 cells passing through the matrigel-coated membrane 
compared to cell cultured with isotype-control antibodies (Fig. 2f), thus confirming the contribution of surface 
alpha-enolase to EGF- and LPS-mediated cell invasion.
These results are in line with data reported for other cancer cells, where the stable overexpression or the 
knocking down of alpha-enolase was shown to promote or inhibit cell invasion, respectively5, 6, 14, 20–22, our data 
are novel for non-tumourigenic mammary epithelial cells.
Surface alpha-enolase and membrane Hsp70 share a common response to EGF and LPS. To 
further explore the effect of EGF and LPS treatments on alpha-enolase localization to the plasma membrane, 
we developed a live on-cell western technique that quantitatively measures plasma membrane alpha-enolase by 
imaging living cells. We performed such analysis on HB2, MCF-7 and the doxorubicin-resistant counterpart, 
MCF-7R. All three cell lines express EGFR and TLR4 receptors, although at different levels; notably, MCF-7R 
has lost E-cadherin expression and acquired Vimentin, while showing higher levels of EGFR and alpha-enolase 
(Fig. 3a), all features of cancer cell aggressive phenotype. Matrigel invasion assay confirmed the increased invasive 
Figure 3. Live on-cell western recapitulates live immunofluorescence staining data. (a) Comparative 
immunoblotting analyses of total proteins from HB2, MCF-7 and MCF-7R cells with antibodies against cell 
surface receptors, i.e. TLR4 and EGFR, E-cadherin (E-cad), Vimentin (Vim) and alpha-enolase (α-Eno). 
β-actin is shown as a control of the total proteins loaded per lane. (b) Representative image of the infrared 
signal emission from a 96-well tissue culture plate processed by live on-cell western with the indicated primary 
antibodies. The image shows ten duplicate wells/cell type of confluent HB2, MCF-7 and MCF-7R cells in 
control conditions (−) or after treatment (+) with 5 µg/ml LPS or 0.1 µg/ml EGF, for 24 hours. The omission 
of primary antibodies (sec.) is shown as a control of specificity. (c) The bar graph shows the relative mean 
infrared intensity for live on-cell western analyses, corrected for nuclei staining. Each data point is the average 
of three independent experiments, error bars represent standard deviation and p values (*P < 0.05, **P < 0.01, 
***P < 0.001) indicate statistical significance relative to the untreated control.
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capacity of MCF-7R cells compared to the parental MCF-7 cells (supplementary Fig. 2), behaviour which is con-
sistent with the acquisition of doxorubicin resistance23.
Antibodies directed against extracellular epitopes of TLR4, EGFR and alpha-enolase, respectively, were used 
to set up experimental conditions for assessing the localization of the selected proteins on the cell surface of live 
cells by the on-cell western approach.
Figure 3b shows the red-scale infrared signal at 700 nm measured using an infrared imaging system from a 
96-well tissue culture plate; the fluorescent signals were quantified on a fluorescent scanner, normalizing to the 
approximate number of cells, measured by nuclear staining. As expected, the analysis indicated that all three cell 
lines expressed TLR4 and EGFR on their surface, and the relative expression in each cell line was consistent with 
the overall expression level detected in total cell lysates (compare Fig. 3a and c). Alpha-enolase was expressed on 
the surface of the three cell lines, and its amount correlated with the tumourogeneity and invasiveness of cells, as 
the doxorubicin-resistant MCF-7R showed the highest steady-state level of expression (Fig. 3c).
Next, we performed EGF and LPS treatments and measured the expression of surface alpha-enolase; we also 
evaluated the levels of plasma membrane Hsp70, another multifunctional protein detected on the cell surface 
of human and mouse tumours, using an antibody specifically recognizing membrane-bound Hsp7024. The rel-
ative mean infrared signal intensities indicated that all three cell lines respond to EGF and LPS exposure by 
upregulating alpha-enolase on their surface, and, surprisingly, we also detected an increased expression of mem-
brane Hsp70 (Fig. 3b and c). The on-cell western blot recapitulated and corroborated what had been previously 
observed by subcellular fractionation and immunofluorescence analysis (Figs 1 and 2) and, as a novel finding, 
suggested that the trafficking of the intracellular chaperone Hsp70 to the cell membrane may share a common 
pathway with alpha-enolase.
Alpha-enolase interacts with Hsp70. Cell surface alpha-enolase and Hsp70 showed a common response 
to EGF or LPS exposure by on-cell western of living cells. This observation prompted us to investigate whether 
the two proteins may interact. To test the putative interaction, cytoplasmic HB2, MCF-7 and MCF-7R cell extracts 
were immunoprecipitated with anti-alpha-enolase antibody, followed by immunoblotting with anti-Hsp70 anti-
body. Figure 4a shows that alpha-enolase co-precipitated with Hsp70 but not with Hsp90, another abundant 
chaperone, indicating that the endogenous alpha-enolase and Hsp70 proteins may interact in the cytoplasmic 
compartment and that alpha-enolase is not a classical Hsp90 “client” protein25.
The protein-protein interaction analysis was further extended to the cell surface compartment; native 
plasma membrane fractions were isolated from HB2, MCF-7 and MCF-7R cells and immunoprecipitated with 
anti-alpha-enolase or anti-Hsp70 antibodies, then the precipitated complexes were probed with antibodies 
against a selected group of proteins. No co-precipitation of EGFR or TFR receptor, GAPDH or Hsp90 protein 
was detected, neither with endogenous alpha-enolase nor with Hsp70 (Fig. 4b). Conversely, the newly identified 
interaction between alpha-enolase and Hsp70 and the previously reported interactions of alpha-enolase with 
Annx2, Cav-1 and urokinase plasminogen activator receptor (uPAR)5, 14 were confirmed in the plasma mem-
brane subcellular fraction. Interestingly, the co-immunoprecipitation results indicated the association of Hsp70 
with the alpha-enolase interactors, namely Annx2 and Cav-1, but not with uPAR (Fig. 4b), suggesting either the 
presence of a plasma membrane multiprotein complex and/or a route of translocation to the cell surface common 
to alpha-enolase and Hsp70.
Next, we performed an in situ Proximity Ligation Assay (PLA) in live cells to further examine the nature of the 
interaction between alpha-enolase and Hsp70 on the cell surface. The detection of a positively amplified signal by 
this method indicates that two selected proteins are located within 40 nm of each other, thus visualizing protein 
localization in close proximity or co-localization. Figure 4c shows that alpha-enolase was found to co-localize 
with Hsp70 in the plasma membrane and, as previously reported by Hsiao and colleagues, with uPAR5, while no 
positively amplified signal was detected using antibodies against EGFR or isotype-matched controls. Consistently 
with the co-immunoprecipitation data, the PLA results supported by other means that alpha-enolase and Hsp70 
interact with each other on the cell surface.
The surface expression of alpha-enolase is downregulated by Hsp70 knockdown. To explore the 
functional role of Hsp70 in the subcellular localization of alpha-enolase, we silenced Hsp70 by siRNA transfection 
in HB2, MCF-7 and MCF-7R cells. Firstly, Hsp70 expression was monitored in total cell extracts to assess the 
extent of silencing; we detected about 70% of expression reduction in all three cell lines (Fig. 5a,b). Hsp70 knock-
down did not influence total alpha-enolase expression in MCF-7 and MCF-7R cells, and to some extent affected 
total level (about 30% reduction) in non-tumourigenic HB2 cells, which express less alpha-enolase (Fig. 5a,b). 
Conversely, in all three cell lines the on-cell western analyses showed a substantial and comparable downregula-
tion of membrane Hsp70 and, to a larger extent, of surface-localized alpha-enolase in silenced cells with respect 
to controls treated with unrelated siRNA (Fig. 5c,d).
Finally, to further investigate the involvement of Hsp70 in the localization of alpha-enolase to the plasma 
membrane, the effects of Hsp70 silencing on EGF and LPS treatments were explored in HB2, MCF-7 and MCF-7R 
cells by the on-cell western approach. Figure 5d shows how the knockdown of Hsp70 counteracted the EGF- and 
LPS-mediated upregulation of alpha-enolase in the plasma membrane compartment, drastically reducing surface 
alpha-enolase compared to the control cells. The effect of Hsp70 knockdown is specific for surface alpha-enolase, 
since the total level of alpha-enolase was not affected in breast cancer cells. Collectively, these data strongly sup-
ported a functional role of the interacting protein Hsp70 in regulating alpha-enolase surface localization.
Discussion
Elevated levels of alpha-enolase expression have been reported for many cancer types, and alterations of cyto-
solic enzyme levels have been widely considered a biomarker of malignancy26, 27. In addition to its major role in 
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glycolysis, the alpha-enolase protein performs multiple functions, depending on its subcellular localization: a 
nuclear short variant, Myc promoter-binding protein 1 (MBP-1), acts as a transcriptional repressor, while the 
cytosolic protein, when translocated to the cell surface, binds to plasminogen, contributing to pericellular plas-
min production and cell motility. So far, no other roles have been elucidated for the protein exposed on the cell 
membrane, while an additional function, still poorly investigated, is likely to be exerted by the alpha-enolase 
secreted in extracellular vesicles; notably, alpha-enolase is reported to be among the most abundant proteins in 
exosomes28.
The nuclear short form, MBP-1 and the protein localized to cell surface have attracted attention from research-
ers for their involvement in tumour growth, invasion and metastasis development29, 30. A role for MBP-1 in 
Figure 4. Interaction between Hsp70 and alpha-enolase. (a) Association of endogenous Hsp70 and alpha-
enolase proteins in the cytoplasmic fraction of HB2, MCF-7 and MCF-7R cells. Cytoplasmic extracts were 
immunoprecipitated with anti-alpha-enolase monoclonal antibody (IP: α-Eno) or a pre-immune isotype-
matched antibody (IP: IgG), then analysed by immunoblotting using anti-Hsp70 polyclonal antibody, anti-
alpha-enolase polyclonal and anti-Hsp90 monoclonal antibody. Input represents 4% of the cell extract used 
for each IP sample. Hsp70 was specifically co-immunoprecipitated with alpha-enolase in the three cell lines. 
(b) Association of endogenous Hsp70 and alpha-enolase proteins in the plasma membrane fraction of HB2, 
MCF-7 and MCF-7R cells. Plasma membrane fractions were immunoprecipitated with anti-alpha-enolase 
monoclonal antibody (IP: α-Eno) or anti-Hsp70 monoclonal antibody (IP: Hsp70). Immunoprecipitated 
complexes were analysed by immunoblotting for the presence of the indicated proteins. Annx2, Cav-1 and 
uPAR were used as positive controls for alpha-enolase interactions. No co-precipitation of EGFR, TFR, 
GAPDH or Hsp90 was observed with either Hsp70 or alpha-enolase, while Annx2 and Cav-1 were specifically 
co-immunoprecipitated with both proteins. Note that Cav-1 expression is undetectable in the MCF-7 plasma 
membrane fraction compared to the other cell lines. Hsp70 was specifically co-immunoprecipitated with alpha-
enolase, and, similarly, alpha-enolase was specifically co-immunoprecipitated with Hsp70. Input represents 6% 
of the cell extract used for each IP sample. (c) Representative images of PLA assay detecting the proximity of 
surface-localized alpha-enolase and Hsp70. HB2 cells were live-stained with alpha-enolase-specific antibody 
together with anti-Hsp70 (α-Eno, Hsp70), anti-uPAR (α-Eno, uPAR), anti-EGFR (α-Eno, EGFR) and nuclei 
counterstained with DAPI (blue). A positive amplified signal (red) indicated that alpha-enolase and either 
Hsp70 or uPAR (positive control) were co-located within 40 nm, while no signal was obtained after incubation 
with either anti-EGFR or isotype-matched antibody (right panels). Results are representative of three 
independent experiments with comparable outcomes.
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down-regulating tumour invasion and metastasis has been proposed for gastric cancer using mouse xenograft 
models31, and MBP-1 expression has been positively correlated to patient outcomes in primary invasive ductal 
carcinoma of the breast32. More recently, antibodies targeting surface-localized alpha-enolase have been shown 
to inhibit the metastatic spreading of lung cancer cells and pancreatic adenocarcinoma cells in immunosup-
pressed mice5, 6. Proteomics-based studies on purified plasma membranes have confirmed the surface locali-
zation of alpha-enolase in lung, pancreatic and breast cancer cells33–35. A few studies in yeast and mammalian 
cells have indicated the presence of enolase in discrete membrane regions, i.e. membrane rafts36, 37. Moreover, 
Wygrecka’s group has demonstrated the interaction of alpha-enolase with Cav-1 and Annx2 in the highly invasive 
MDA-MB-231 cell line and proposed that the altered levels of intracellular Ca2+ play a pivotal role in the regula-
tion of translocation from the cytosolic compartment to the plasma membrane10, 14.
In this study, we have focused on surface-localized alpha-enolase, adding novel insights to the stimuli and 
interactors contributing to its cell surface expression, which ultimately might be the prerequisite for a further 
release of the protein into the extracellular space.
Here, we have demonstrated for the first time that EGF signalling is involved in the up-regulation of 
surface-localized alpha-enolase both in non-tumourigenic mammary epithelial cells and in breast cancer cells, 
independently from the steady-state level of surface expression and the metastatic potential of each cell type. 
Our data also confirm previously studies identifying LPS exposure among the stimuli that upregulate cell surface 
alpha-enolase in monocytoid cells and breast cancer cells7, 10, in accordance to the presence of TLR4 receptors in 
Figure 5. The knockdown of Hsp70 negatively affects surface-localized alpha-enolase. (a) HB2, MCF-7 
and MCF-7R cells were treated with Hsp70-specific siRNA (+) or unrelated siRNA as a control (−), and 
immunoblotting analysis of total lysates with anti-Hsp70 and anti-alpha-enolase (α-Eno) was performed. 
β-actin is shown as a control of the total proteins loaded per lane. (b) Quantification of Hsp70 and alpha-enolase 
in Hsp70-silenced cells. Data were normalised to the densitometric signals of β-actin and expressed relative to 
the level detected in cells treated with unrelated siRNA (siControl), set at 1. (c,d) Live on-cell western of Hsp70-
silenced cells. The bar graph in (c) shows the relative mean infrared intensity for membrane Hsp70, corrected 
for nuclei staining. Transiently-silenced cells were either untreated or treated with 5 µg/ml LPS or 0.1 µg/ml EGF 
for 24 hours, and then analysed for the expression of surface-localized alpha-enolase by on-cell western (d). 
Results are the average of three independent experiments, error bars represent standard deviation and p values 
(*P < 0.05, **P < 0.01, ***P < 0.001) indicate statistical significance relative to the untreated control.
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both cell types9, 38, 39. The results are in agreement with the notion that stimuli promoting tumour progression, as 
demonstrated for TGF-α, TNF-α and CCL2 in MDA-MB-231 cells10, trigger surface alpha-enolase expression.
A further novel finding of this study concerns the interaction of surface-localized alpha-enolase with 
another multifunctional protein, Hsp70, the major stress-inducible member of the Hsp70 family. This pro-
tein, like alpha-enolase, does not present a consensual secretory signal; nevertheless, a lot more is known about 
membrane-bound Hsp70, which translocates to the plasma membrane after stress and is released into the extra-
cellular environment in a membrane-associated form that is capable of activating immune cells40. In tumour cells, 
but not in non-malignantly transformed cells, Hsp70 appears to be stably associated with the plasma membrane41.
We have shown for the first time that Hsp70, like alpha-enolase, in response to EGF and LPS stimuli, is over-
expressed in the plasma membrane where the two proteins co-localize and interact, likely in discrete mem-
brane regions. As an additional insight towards the understanding of the molecular mechanisms underlying the 
localization of alpha-enolase to the cell membrane, we propose a functional involvement of Hsp70, which may 
contribute to alpha-enolase transport and/or stabilization on the plasma membrane. This hypothesis is strongly 
supported by the fact that the two proteins interact in the cytoplasm and the plasma membrane subcellular com-
partments, and that silencing Hsp70 expression resulted in a specific downregulation of the surface alpha-enolase 
steady-state level, as well as in the inhibition of EGF- and LPS-mediated effects.
More in-depth studies are needed to fully dissect the signalling pathways and the molecular mechanism(s) 
leading to the cell surface exposure of alpha-enolase and to clarify the existence of specific membrane subdo-
mains, where enolase and its interactors may contribute to multiple functions in addition to plasminogen bind-
ing, both in non-tumourigenic and cancer cells.
Methods
Reagents. LPS and EGF were purchased from Sigma-Aldrich, n-Octyl-D-glucoside was purchased from 
Santa Cruz Biotechnology. Primary antibodies were: mouse monoclonals Eno 276/3 and 72/1 against alpha-eno-
lase19; mouse monoclonal cmHsp70.1 against membrane Hsp7024; goat anti-alpha-enolase, rabbit anti-E-cad-
herin, mouse anti-Hsp90, rabbit anti-Hsp70, goat anti-GAPDH, rabbit and mouse anti-EGFR, mouse anti-TFR, 
rabbit anti-uPAR, rabbit anti-Vimentin, goat anti-Lamin B (Santa Cruz Biotechnology); rabbit anti-phospho-Akt, 
mouse anti-Akt, rabbit anti-Phospho-p44/42 MAPK (Erk1/2) (Cell Signaling Technologies); mouse anti-ERK1/2 
(Proteintech Group), mouse anti-β-actin (Sigma-Aldrich); rabbit anti-TLR4 (Novus Biologicals); rabbit anti-Ca-
veolin-1 (Upstate Biotechnology); mouse anti-Annexin-A2 (BD Biosciences). Alexa Fluor-conjugated secondary 
antibodies were purchased from ThermoFisher Scientific Inc.
Cell culture. The human MCF-7 breast cancer cell line was purchased from American Type Culture 
Collection (ATCC, Rockville, MD, USA); the doxorubicin-resistant counterpart, MCF-7R42, and the human 
HB2 non-tumourigenic mammary epithelial cell line15 were kindly provided by Natale D’Alessandro and Ida 
Pucci-Minafra (University of Palermo, Italy), respectively. MCF-7 and MCF-7R cells were cultured in Dulbecco’s 
modified Eagle medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), glutamine 
(4 mM) and penicillin/streptomycin (100 μg/ml). For HB2 cells, culture medium (DMEM low-glucose) was sup-
plemented with hydrocortisone (5 μg/ml) and bovine insulin (10 μg/ml).
For treatment with EGF (0.1 µg/ml) and LPS (0.1, 1 or 5 µg/ml), cells were plated at a density of 2 × 104/
cm2, cultured in complete culture medium for 24 hours, then serum-starved overnight. Cells were stimulated in 
serum-free medium supplemented with the indicated quantity of ligands for an additional 24 hours.
Wound-healing assay. HB2 and MCF-7 cells were grown near to confluence in a 6-well plate and 
serum-starved overnight. A scratch was made on the cell monolayer using a sterile pipette tip, and cells were 
treated with either EGF or LPS (0.1 µg/ml) or left untreated in fresh serum-free medium for 24 hours. Pictures 
were captured by a Leica DM IL LED microscope at 0, 6 and 24 hours after scratching. The rate of wound closure 
was assessed by measuring the distance between the migrating cell boundaries. All experiments were performed 
in triplicate.
Cell Invasion Assay. For cell invasion assay, serum-free medium (750 μl) with or without EGF (0.1 µg/ml) or 
LPS (5 µg/ml) was added into the lower chambers of a 24 transwell plate, 2 × 104 cells were seeded into the upper 
chamber coated with matrigel (8.0-μm pore size, Corning). After 48 hours of incubation, non-migrating cells 
were removed with a cotton swab and cells that had migrated at the bottom of the membrane were fixed with ice 
cold acetone/methanol (1:1) and stained with crystal violet (0.5% in 20% methanol) for 1 h. The cells located on 
the underside of the filter were photographed by phase contrast microscopy (x100 magnification) and counted 
(5 fields/filter). The experiments were performed in triplicate. Where indicated, mouse anti-alpha enolase 72/1 
(50 µg/ml) and goat anti-alpha-enolase (15 µg/ml) or isotype-matched control antibody were added to the appro-
priate inserts for 24 hours; thereafter, cells were processed as described.
Cell extracts and immunoblotting. Total protein extracts were prepared as previously described43, cyto-
plasmic and total membrane fractions were isolated using the Calbiochem ProteoExtract Subcellular Proteome 
Extraction Kit, and native plasma membranes were obtained with the BioVision Membrane Protein Extraction 
Kit, according to the manufacturers’ instructions. All buffers were supplemented with protease and phosphatase 
inhibitor cocktails (Sigma-Aldrich), and protein concentrations were determined by the Bradford protein assay 
(Bio-Rad Laboratories).
Total proteins or cytoplasmic extracts (20–30 μg) and corresponding total membrane cell equivalents were 
separated on 10% polyacrylamide gels (SDS-PAGE) or NuPage Novex 4–12% Bis-Tris precast gels (ThermoFisher 
Scientific Inc.), and then transferred onto a nitrocellulose membrane. Primary antibodies were revealed with 
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secondary antibodies, either conjugated to IRDye® 800CW (LI-COR) or Alexa Fluor 680, using the Odyssey 
infrared imaging system (LI-COR Biosciences) according to the manufacturer’s instructions.
Normalization for total proteins was based on β-actin signals, whereas the densitometric signals of reversible 
Ponceau S staining were used to normalize cytoplasmic and total membrane fractions44.
Co-immunoprecipitation. For the co-immunoprecipitation of plasma membrane proteins, the final mem-
brane pellet from the Biovision Kit was re-suspended in Phosphate-buffered saline (PBS) containing 1% Triton 
X-100, 60 mM n-Octyl-D-glucoside, 2 mM EDTA, and supplemented with protease and phoshatase inhibitors 
(Sigma-Aldrich). Plasma membrane proteins (180 μg) or the corresponding cytoplasmic extract (500 μg) were 
incubated overnight with mouse monoclonal antibodies (10 μg), either against alpha-enolase (Eno 276/3) or 
surface Hsp70 (cmHsp70.1), which had been previously cross-linked to agarose beads using the Cross-linking 
Immunoprecipitation Kit from ThermoFisher Scientific. The specificity of the precipitated immunocomplexes 
was assessed using IgG isotype controls. The immunoprecipitated proteins were eluted off the beads, incubated 
in a low pH buffer for 5 minutes at room temperature, separated on a 4–12% Bis-Tris Plus Gel (ThermoFisher 
Scientific Inc.) and analysed by immunoblotting.
Immunofluorescence microscopy. Cells were plated at a density of 1.8 × 104 cells/well in LAB-TEK 
Chamber Slide, 8well, and cultured for 24 hours. The next day, cells were serum-starved overnight and then 
treated with either EGF or LPS or left untreated for 24 hours. For live-cell immunofluorescence, cells were incu-
bated with goat anti-alpha-enolase antibodies (4 µg/ml) in DMEM supplemented with 5 mM NaN3, to minimize 
capping and/or recycling of surface proteins, for 30 min at room temperature. After three washings in ice-cold 
PBS plus NaN3 (5 mM) on ice, cells were fixed in 4% paraformaldehyde for 15 min at room temperature. Fixed 
cells were blocked with 1% BSA in PBS for 30 min, and then incubated with rabbit anti-E-cadherin (4 µg/ml) in 
PBS-1% BSA overnight at 4 °C. AlexaFluor 488-conjugated Donkey anti-goat IgG and AlexaFluor 594-conjugated 
Goat anti-rabbit IgG were used as secondary antibodies at a dilution of 1:500 for 1 hour at room temperature. 
DNA was counterstained with 4′6-diamidino-2-phenylindole (DAPI) using Vectashield (Vector Laboratories). 
Primary-antibody omission demonstrated the specificity of the immunostaining. Images were captured using 
an Axioskop 2 plus (Carl Zeiss) microscope equipped with a 40x objective or a FluoView FV10i confocal 
laser-scanning microscope (Olympus) equipped with a 60x oil objective. The fluorescent staining intensity of 
alpha-enolase was quantified using the ImageJ software on at least five representative fields, and data are pre-
sented as means ± standard deviation. All experiments were performed in triplicate.
Live staining by on-cell western. The on-cell western protocol was conducted according to Milovancev et 
al.45, with some modifications. Cells were plated at a density of 0.7 × 104 cells/well in a 96-well plate and cultured 
for 24 hours. After serum-starving overnight, cells were either left untreated or treated with EGF (0.1 µg/ml) or 
LPS (5 µg/ml) in serum-free medium for 24 hours. Live-staining for surface alpha-enolase and surface Hsp70 was 
performed as previously described in the immunofluorescence microscopy section using goat anti-alpha-enolase 
and mouse monoclonal cmHsp70.1 (15 μg/ml), respectively. A mouse monoclonal antibody against EGFR that 
recognizes a cell surface epitope and a rabbit anti-TLR4 binding to the extracellular domain of the receptor were 
used similarly on live cells. The use of antibodies against an intracellular antigen, laminin B, and the omission 
of primary antibody confirmed the specificity of the cell surface staining. After incubation with primary anti-
bodies, cells were fixed in 4% paraformaldehyde, blocked with 1% BSA in PBS for 30 min, then incubated with 
AlexaFluor 680-conjugated secondary antibody (1:2000) in PBS-1% BSA for 1 hour at room temperature. Cell 
were then washed extensively and imaged on a LI-COR scanner. Nuclei were counterstained with Hoechst 33258 
(Sigma-Aldrich) and the fluorescent signal was detected using a fluorescent plate reader (BioRad Laboratories). 
The fluorescent signal from the secondary antibodies was subtracted of blank average signal, and then normalized 
against the Hoechst staining, to account for differences in the number of cells. Each condition had three technical 
replicates, and data are presented as means ± standard deviation of at least three experiments.
Proximity Ligation Assay (PLA). The Duolink in situ PLA (Sigma-Aldrich) was performed following the 
manufacturer’s protocol, with minor modifications. Briefly, cells were cultured and live-stained as they were for 
the immunofluorescence and on-cell western procedures. Cells were incubated in DMEM/5 mM NaN3 with goat 
anti-alpha-enolase plus mouse anti surface Hsp70, or goat anti-alpha-enolase plus rabbit anti-uPAR as a posi-
tive control. All antibodies were used at a concentration of 15 μg/ml. Live-staining with goat anti-alpha-enolase 
plus mouse anti-EGFR was performed as a negative control. Omission of antibodies or incubation with 
isotype-matched pre-immune antibodies further demonstrated the specificity of the PLA reaction. The next steps, 
such as incubation with specific secondary antibodies and a connector oligonucleotide, enzymatic DNA ligation 
in the PLA ligation buffer, and polymerase amplification of the ligation products, were performed as recom-
mended. Finally, fluorescence-labeled oligonucleotides complementary to the sequence on the circle were added, 
and nuclei were counterstained with DAPI. Fluorescent signals were visualized using a FluoView FV10i confocal 
laser-scanning microscope (Olympus) equipped with a 60x oil objective.
Small interfering RNA (siRNA) transfection. HB2, MCF-7 and MCF-7R cells (2 × 105) were reverse 
transfected with human Hsp70 siRNA (Santa Cruz) or control siRNA (AllStars, Qiagen) at a final concentra-
tion of 30 nM, using Lipofectamine RNAiMAX transfection reagent according to the manufacturer’s instruc-
tions (ThermoFisher Scientific Inc.). Cells were processed for immunoblotting and on-cell western 48 hours after 
transfection.
www.nature.com/scientificreports/
1 1Scientific RepoRts | 7: 3841  | DOI:10.1038/s41598-017-04185-8
Statistical analysis. All data are presented as means ± standard deviation of at least three experiments. The 
statistical significance of differences following EGF and LPS treatment was assessed by paired, one-sided Student’s 
T-Test; statistical differences are presented at probability levels of *P < 0.05, **P < 0.01, ***P < 0.001.
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